0001140361-24-009025.txt : 20240222
0001140361-24-009025.hdr.sgml : 20240222
20240222160622
ACCESSION NUMBER: 0001140361-24-009025
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240220
FILED AS OF DATE: 20240222
DATE AS OF CHANGE: 20240222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hopper Jonathan Mark
CENTRAL INDEX KEY: 0001626325
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35280
FILM NUMBER: 24664711
MAIL ADDRESS:
STREET 1: 64 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vericel Corp
CENTRAL INDEX KEY: 0000887359
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 943096597
STATE OF INCORPORATION: MI
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 7349305555
MAIL ADDRESS:
STREET 1: 64 SIDNEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC
DATE OF NAME CHANGE: 19960428
4
1
form4.xml
FORM 4
X0508
4
2024-02-20
0000887359
Vericel Corp
VCEL
0001626325
Hopper Jonathan Mark
64 SIDNEY STREET
CAMBRIDGE
MA
02139
true
Chief Medical Officer
false
Common Stock
2024-02-20
4
M
0
3000
0
A
56984
D
Common Stock
2024-02-20
4
F
0
1379
49.5
D
55605
D
Common Stock
2024-02-20
4
M
0
2325
0
A
57930
D
Common Stock
2024-02-20
4
F
0
985
49.5
D
56945
D
Common Stock
2024-02-20
4
M
0
1750
0
A
58695
D
Common Stock
2024-02-20
4
F
0
742
49.5
D
57953
D
Restricted Stock Unit
2024-02-20
4
M
0
3000
A
Common Stock
3000
9000
D
Restricted Stock Unit
2024-02-20
4
M
0
2325
A
Common Stock
2325
4650
D
Restricted Stock Unit
2024-02-20
4
M
0
1750
A
Common Stock
1750
1750
D
The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively.
These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2025, and February 18, 2026, respectively.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest on February 19, 2025.
Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
No expiration date for this type of award.
The Fair Market Value of the vested derivative securities is $49.50 per share.
/s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
2024-02-22